Article (Scientific journals)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
Baron, Frédéric; Maris, M. B.; Storer, B. E. et al.
2005In Biology of Blood and Marrow Transplantation, 11 (4), p. 272-279
Peer Reviewed verified by ORBi
 

Files


Full Text
BaronCMLBBMT05.pdf
Publisher postprint (156.47 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
chronic myeloid leukemia; hematopoietic cell transplantation; unrelated donor; non-myeloblative; chimerism; graft rejection
Abstract :
[en] We evaluated 10/10 HLA antigen-matched unrelated hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with fludarabine 3 x 30 mg/m(2) and 2 Gy of total body irradiation as treatment for patients with chronic myeloid leukemia who were ineligible for conventional HCT. Data from 21 consecutive patients in first chronic phase (CP1; n = 12), accelerated phase (AP; n = 5), second CP (CP2; n = 3), and blast crisis (n = 1) were analyzed. Stem cell sources were bone marrow (n = 4) or granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMCs; n = 17). The patient who underwent transplantation in blast crisis died on day 21 (too early to be evaluated. for engraftment) from progressive disease. Sustained engraftment was achieved in 5 of 12 patients who underwent transplantation in CP1, 4 of 5 patients who underwent transplantation in AP, and 2 of 3 patients who underwent transplantation in CP2, whereas 9 patients rejected their grafts between 28 and 400 days after HCT. Specifically, I of 4 marrow recipients and 10 of 17 G-PBMC recipients achieved sustained engraftment. Graft rejections were nonfatal in all cases and were followed by autologous reconstitution with persistence or recurrence of chronic myeloid leukemia. Seven of 11 patients with sustained engraftment-including all 5 patients in CP 1, 2 of 4 patients in AP, and neither of the 2 patients in CP2-were alive in complete cytogenetic remissions 118 to 1205 days (median, 867 days) after HCT. Two of the remaining 4 patients died of nonrelapse causes in complete (n = 1) or major (n = 1) cytogenetic remissions, and 2 died of progressive disease. Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression. (c) 2005 American Society for Blood and Marrow Transplantation.
Disciplines :
Immunology & infectious disease
Hematology
Surgery
Author, co-author :
Baron, Frédéric  ;  Université de Liège - ULiège > Département des sciences cliniques > Hématologie
Maris, M. B.
Storer, B. E.
Sandmaier, B. M.
Stuart, M. J.
McSweeney, P. A.
Radich, J. P.
Pulsipbek, M. A.
Agura, E. D.
Chauncey, T. R.
Maloney, D. G.
Shizuru, J. A.
Storb, R.
More authors (3 more) Less
Language :
English
Title :
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
Publication date :
April 2005
Journal title :
Biology of Blood and Marrow Transplantation
ISSN :
1083-8791
eISSN :
1523-6536
Publisher :
Carden Jennings Publ Co Ltd, Charlottesville, United States - Virginia
Volume :
11
Issue :
4
Pages :
272-279
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 November 2011

Statistics


Number of views
62 (0 by ULiège)
Number of downloads
214 (0 by ULiège)

Scopus citations®
 
43
Scopus citations®
without self-citations
23
OpenCitations
 
42

Bibliography


Similar publications



Contact ORBi